Compugen Ltd. (CGEN)
CGEN Stock Price Chart
Explore Compugen Ltd. interactive price chart. Choose custom timeframes to analyze CGEN price movements and trends.
CGEN Company Profile
Discover essential business fundamentals and corporate details for Compugen Ltd. (CGEN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
11 Aug 2000
Employees
74.00
Website
https://cgen.comCEO
Eran Ophir
Description
Compugen Ltd., an Israeli-based company established in 1993 and headquartered in Holon, is a clinical-stage enterprise focused on the discovery, development, and commercialization of therapeutic and product candidates. Its operations extend across Israel, the United States, and Europe. The company’s core activities center around its immuno-oncology pipeline, which includes several investigational treatments: COM701, an anti-PVRIG antibody currently undergoing Phase I clinical studies for solid tumors. COM902, a therapeutic antibody designed to target TIGIT, which is also in Phase I clinical trials as a monotherapy for advanced malignancies. Bapotulimab, an antibody targeting ILDR2, presently in Phase I clinical development for solid tumor indications. AZD2936, an innovative bispecific antibody targeting both TIGIT and PD-1, advancing through Phase I/II clinical studies for patients with advanced or metastatic non-small cell lung cancer. Additionally, Compugen maintains earlier-stage immuno-oncology programs, with a particular emphasis on myeloid targets. To further its research and development, Compugen actively fosters strategic alliances. It has a collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics that modulate immune checkpoint regulators. Another key partnership is with Bristol-Myers Squibb, aimed at evaluating the safety and tolerability of COM701 when administered alongside Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor, Opdivo, in patients with advanced solid tumors. The company also collaborates with Johns Hopkins School of Medicine to investigate novel T cell and myeloid checkpoint targets, and has a distinct research collaboration with Johns Hopkins University specifically dedicated to myeloid science. Furthermore, Compugen holds a licensing agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products.
CGEN Financial Timeline
Browse a chronological timeline of Compugen Ltd. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 Aug 2026
EPS estimate is -$0.07, while revenue estimate is $1.28m.
Earnings released on 18 May 2026
EPS came in at -$0.08 falling short of the estimated -$0.07 by -14.29%, while revenue for the quarter reached $2.18m , beating expectations by +38.47%.
Earnings released on 2 Mar 2026
EPS came in at $0.60 surpassing the estimated -$0.07 by +957.14%, while revenue for the quarter reached $67.33m , beating expectations by +3.02k%.
Earnings released on 10 Nov 2025
EPS came in at -$0.07 surpassing the estimated -$0.09 by +22.22%, while revenue for the quarter reached $1.89m , beating expectations by +61.85%.
Earnings released on 6 Aug 2025
EPS came in at -$0.08 falling short of the estimated -$0.07 by -14.29%, while revenue for the quarter reached $1.26m , missing expectations by -68.19%.
Earnings released on 19 May 2025
EPS came in at -$0.08 falling short of the estimated -$0.06 by -33.33%, while revenue for the quarter reached $2.28m , missing expectations by -28.46%.
Earnings released on 4 Mar 2025
EPS came in at -$0.07 falling short of the estimated $0.07 by -200.00%, while revenue for the quarter reached $1.47m , missing expectations by -88.70%.
Earnings released on 12 Nov 2024
EPS came in at $0.01 falling short of the estimated $0.06 by -83.33%, while revenue for the quarter reached $17.10m , beating expectations by +1.24k%.
Earnings released on 6 Aug 2024
EPS came in at -$0.02 surpassing the estimated -$0.08 by +75.00%, while revenue for the quarter reached $6.70m , beating expectations by +303.33%.
Earnings released on 20 May 2024
EPS came in at -$0.08 surpassing the estimated -$0.10 by +20.00%, while revenue for the quarter reached $2.56m , beating expectations by +5.53%.
Earnings released on 5 Mar 2024
EPS came in at $0.11 surpassing the estimated $0.10 by +10.00%, while revenue for the quarter reached $33.46m , beating expectations by +67.30%.
Earnings released on 7 Nov 2023
EPS came in at -$0.11 falling short of the estimated -$0.09 by -22.22%, while revenue for the quarter reached $8.00m , beating expectations by +113.33%.
Earnings released on 7 Aug 2023
EPS came in at -$0.11 surpassing the estimated -$0.13 by +15.38%.
Earnings released on 15 May 2023
EPS came in at -$0.11 surpassing the estimated -$0.12 by +8.33%.
Earnings released on 27 Feb 2023
EPS came in at -$0.04 surpassing the estimated -$0.14 by +71.43%, while revenue for the quarter reached $7.50m .
Earnings released on 14 Nov 2022
EPS came in at -$0.14 falling short of the estimated -$0.13 by -7.69%.
Earnings released on 4 Aug 2022
EPS came in at -$0.11 surpassing the estimated -$0.12 by +8.33%.
Earnings released on 16 May 2022
EPS came in at -$0.11 surpassing the estimated -$0.12 by +8.33%.
Earnings released on 24 Feb 2022
EPS came in at -$0.10 surpassing the estimated -$0.15 by +33.33%.
Earnings released on 12 Nov 2021
EPS came in at -$0.07 surpassing the estimated -$0.13 by +46.15%, while revenue for the quarter reached $6.00m , missing expectations by -21.57%.
Earnings released on 28 Jul 2021
EPS came in at -$0.11 surpassing the estimated -$0.12 by +8.33%.
CGEN Stock Performance
Access detailed CGEN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
